EP1129771B1 - Mikrokapseln - Google Patents
Mikrokapseln Download PDFInfo
- Publication number
- EP1129771B1 EP1129771B1 EP00104745A EP00104745A EP1129771B1 EP 1129771 B1 EP1129771 B1 EP 1129771B1 EP 00104745 A EP00104745 A EP 00104745A EP 00104745 A EP00104745 A EP 00104745A EP 1129771 B1 EP1129771 B1 EP 1129771B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- carbon atoms
- alcohols
- esters
- und
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/10—Complex coacervation, i.e. interaction of oppositely charged particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
Definitions
- the invention is in the field of encapsulation of active ingredients and relates new microcapsules, a process for their preparation and their use in the field cosmetics, pharmacy and food additives.
- microcapsule refers to spherical aggregates with a diameter in the Range of about 0.1 to about 5 mm understood that at least one solid or liquid Core enclosed by at least one continuous shell. More accurate said to be coated with film-forming polymers finely dispersed liquid or solid phases in which the polymers are produced after emulsification and coacervation or precipitate surface polymerization on the material to be enveloped.
- liquid active substances are incorporated in a matrix (“microsponge”), which are additionally enveloped as microparticles with film-forming polymers can.
- the microscopic capsules, also called nanocapsules can be like Dry powder.
- mononuclear microcapsules are also multinucleated aggregates, too Microspheres, known as the two or more cores in the continuous shell material distributed.
- Mononuclear or polynuclear microcapsules can also from an additional second, third, etc. sheath be enclosed.
- the shell can be made of natural, semisynthetic or synthetic materials.
- wrapping materials are, for example Gum arabic, agar-agar, agarose, maltodextrins, alginic acid or its salts, e.g.
- Semisynthetic shell materials are among others chemically modified celluloses, in particular cellulose esters and ethers, e.g. cellulose acetate, Ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose and carboxymethylcellulose, and starch derivatives, in particular starch ethers and esters.
- synthetic Shell materials are, for example, polymers such as polyacrylates, polyamides, polyvinyl alcohol or polyvinylpyrrolidone.
- microcapsules of the prior art are the following commercial products (in parentheses is the shell material): Hallcrest Microcapsules (gelatin, gum arabic), Coletica Thalaspheres (marine collagen), Lipotec Millicapseln (alginic acid, agar-agar), Induchem Unispheres (lactose , microcrystalline cellulose, hydroxypropylmethylcellulose); Unicerin C30 (lactose, microcrystalline cellulose, hydroxypropyl methylcellulose ), Kobo Glycospheres (modified starch, fatty acid esters, phospholipids), Softspheres (modified agar-agar) and Kuhs Probiol Nanospheres (phospholipids).
- German patent application DE 19712978 A1 (Henkel) from which chitosan microspheres are known, which are obtained by mixing chitosans or chitosan derivatives with oil bodies and introducing these mixtures into alkali-adjusted surfactant solutions.
- German patent application DE 19756452 A1 (Henkel) also discloses the use of chitosan as encapsulating material for tocopherol.
- the release of the active ingredients from the microcapsules usually takes place during use the preparations containing them by destruction of the shell due to mechanical, thermal, chemical or enzymatic action.
- the disadvantage is that the microcapsules the controlled release of the active ingredients from their interior or not only inadequate allow and the capsules insufficient stability in the presence of surfactants, especially anionic surfactants.
- the task of the present The invention thus consisted in overcoming precisely these disadvantages.
- the new microcapsules are formed by coacervation between the anionic polymers and the cationic chitosans, which at the lipophilic interfaces of the O / W emulsion droplets takes place. In this way, it is also possible to encapsulate such substances, where this is usually very difficult. In addition, the microcapsules are characterized a significantly improved surfactant stability.
- All of the active substances mentioned are usually in concentrations, based on the microcapsules from 0.001 to 10, preferably 0.5 to 5 and in particular 1 to 2 wt .-% used.
- oil bodies which form constituents of the O / W emulsions are Guerbet alcohols based on fatty alcohols containing 6 to 18, preferably 8 to 10, carbon atoms, esters of linear C 6 -C 22 fatty acids with linear or branched C 6 -C 22 Fatty alcohols or esters of branched C 6 -C 13 -carboxylic acids with linear or branched C 6 -C 22 fatty alcohols, such as myristyl myristate, myristyl palmitate, myristyl stearate, myristyl isostearate, myristyl oleate, myristyl behenate, myristyl erucate, cetyl myristate, cetyl palmitate, cetyl stearate, cetyl isostearate, cetyl oleate, cetyl behenate, Cetylerucat, Stearylmyristat, stearyl palmitate, stearyl ste
- esters of linear C 6 -C 22 -fatty acids with branched alcohols are suitable (compare DE 19756377 A1 ), in particular dioctyl malates, esters of linear and / or branched fatty acids with polyhydric alcohols (such as propylene glycol, dimerdiol or trimer triol) and / or Guerbet alcohols, triglycerides based on C 6 -C 10 fatty acids, liquid mono- / di- / triglyceride mixtures based on of C 6 -C 18 fatty acids, esters of C 6 -C 22 fatty alcohols and / or Guerbet alcohols with aromatic carboxylic acids, in particular benzoic acid, esters of C 2 -C 12 dicarboxylic acids with linear or
- the addition products of ethylene oxide and / or of propylene oxide to fatty alcohols, fatty acids, alkylphenols or castor oil are known, commercially available products. These are mixtures of homologues whose mean degree of alkoxylation corresponds to the ratio of the amounts of ethylene oxide and / or propylene oxide and substrate, with which the addition reaction is carried out corresponds.
- C 12/18 fatty acid mono- and diesters of addition products of ethylene oxide with glycerol are known from DE 2024051 PS as refatting agents for cosmetic preparations.
- Alkyl and / or alkenyl oligoglycosides their preparation and their use are known from the Known in the art. They are prepared in particular by reacting glucose or oligosaccharides with primary alcohols having 8 to 18 carbon atoms.
- primary alcohols having 8 to 18 carbon atoms.
- the glycoside residue is that both monoglycosides in which a cyclic sugar residue Glycosidically linked to the fatty alcohol, as well as oligomeric glycosides with a degree of oligomerization preferably about 8 are suitable.
- the degree of oligomerization is while a statistical mean, the usual for such technical products homolog distribution underlying.
- Suitable partial glycerides are hydroxystearic acid monoglyceride, Hydroxystearic acid diglyceride, isostearic acid monoglyceride, isostearic acid diglyceride, oleic acid monoglyceride, Oleic acid diglyceride, ricinoleic acid glyceride, ricinoleic acid diglyceride, linoleic acid monoglyceride, Linoleic acid diglyceride, linolenic acid monoglyceride, linolenic acid diglyceride, Erucic acid monoglyceride, erucic acid diglyceride, tartaric acid monoglyceride, tartaric acid diglyceride, Citric Acid Monoglyceride, Citron Diglyceride, Malic Acid Monoglyceride, Malic Acid Diglyceride and their technical mixtures, which are subordinate to the manufacturing process may still contain small amounts of triglyceride. Also suitable are addition products from
- the sorbitan esters are sorbitan monoisostearate, sorbitan sesquiisostearate, sorbitan diisostearate, Sorbitan triisostearate, sorbitan monooleate, sorbitan sesquioleate, sorbitan dioleate, Sorbitan trioleate, sorbitan monoerucate, sorbitan sesquierucate, sorbitan butucate, sorbitan trierucate, Sorbitan monoricinoleate, sorbitan squiricinoleate, sorbitan dianicinoleate, sorbitan triricinoleate, Sorbitan monohydroxystearate, sorbitan sesquihydroxystearate, sorbitan dihydroxystearate, Sorbitan trihydroxystearate, sorbitan monotartrate, sorbitan sesquitartrate, sorbitan dandriate, Sorbitan tritartrate, sorbitan monocitrate,
- polyglycerol esters are polyglyceryl-2 dipolyhydroxystearates (Dehymuls® PGPH), polyglycerol-3-diisostearate (Lameform® TGI), polyglyceryl-4 isostearates (Isolan® GI 34), polyglyceryl-3 oleate, diisostearoyl polyglyceryl-3 diisostearate (Isolan® PDI), polyglyceryl-3 methylglucose distearate (Tego Care® 450), polyglyceryl-3 beeswax (Cera Bellina®), Polyglyceryl-4 Caprate (Polyglycerol Caprate T2010 / 90), Polyglyceryl-3 Cetyl ether (Chimexane® NL), polyglyceryl-3 distearate (Cremophor® GS 32) and polyglyceryl Polyricinoleate (Admul® WOL 1403) Polyglyceryl Dimerate I
- polystyrene resin examples include those optionally with 1 to 30 mol Ethylene oxide reacted mono-, di- and triesters of trimethylolpropane or pentaerythritol with lauric acid, coconut fatty acid, tallow fatty acid, palmitic acid, stearic acid, oleic acid, behenic acid and the same.
- the concentration of the emulsifiers can be based on the microcapsules 1 to 10 and preferably 2 to 8 wt .-% amount.
- anionic polymers are in addition to anionic polysaccharides, such as carboxymethylcellulose, or poly (meth) acrylic acids and derivatives thereof, such as salts and esters, preferably salts of alginic acid.
- Alginic acid is a mixture of carboxyl-containing polysaccharides with the following idealized monomer unit:
- the average molecular weight of the alginic acids or alginates is in the range of 150,000 to 250,000.
- Salts of alginic acid are to be understood as meaning both their complete and their partial neutralization products, in particular the alkali metal salts and, preferably, the sodium alginate ("algin") as well as the ammonium and alkaline earth salts.
- mixed alginates such as sodium / magnesium or sodium / calcium alginates.
- anionic chitosan derivatives such as, for example, carboxylating and especially succinylation products are also suitable for this purpose, as described, for example, in German Patent DE 3713099 C2 (L'Oréal) and German Patent Application DE 19604180 A1 (Henkel ) to be discribed.
- the amount used of the anionic polymers is generally - based on the microcapsules - 0.01 to 1, preferably 0.05 to 0.1 wt .-%.
- Chitosans are biopolymers and are counted among the group of hydrocolloids. With the anionic polymers they form membranes. Chemically, they are partially deacetylated chitins of different molecular weight containing the following - idealized - monomer unit:
- chitosans are cationic biopolymers under these conditions.
- the positively charged chitosans can interact with oppositely charged surfaces and are therefore used in cosmetic hair and body care products as well as pharmaceuticals Preparations used (see Ullmann's Encyclopedia of Industrial Chemistry, 5th ed., Vol. A6, Weinheim, Verlag Chemie, 1986, pp. 231-232).
- Surveys on this topic are also for example by B. Gesslein et al. in HAPPI 27 , 57 (1990), O. Skaugrud in Drug Cosm. 148 , 24 (1991) and E. Onsoyen et al.
- chitosans is based on chitin, preferably the shell remains of crustaceans, which are available as cheap raw materials in large quantities.
- the chitin is thereby used in a process first described by Hackmann et al. has been described, usually initially deproteinized by the addition of bases, demineralized by the addition of mineral acids and finally deacetylated by the addition of strong bases, wherein the molecular weights may be distributed over a broad spectrum.
- Corresponding methods are for example made of macromol. Chem. 177 , 3589 (1976) or French patent application FR 2701266 A.
- such types are used as disclosed in German patent applications DE 4442987 A1 and DE 19537001 A1 (Henkel) and having an average molecular weight of 10,000 to 500,000 or 800,000 to 1,200,000 daltons and / or a viscosity according to Brookfield ( US Pat . 1% by weight in glycolic acid) below 5000 mPas, a degree of deacetylation in the range of 80 to 88% and an ash content of less than 0.3% by weight.
- the chitosans are generally used in the form of their salts, preferably as glycolates.
- the amount of chitosans used is preferably in the range from 0.01 to 1, preferably from 0.05 to 0.1,% by weight, based on the microcapsules.
- an O / W emulsion prepared, which in addition to the oil body, water and the active ingredient an effective amount Contains emulsifier.
- this preparation is stirred vigorously with an appropriate amount of an aqueous anionic polymer solution.
- Polysaccharides especially xanthan gum, guar guar, agar-agar, Alginates and tyloses, carboxymethylcellulose and hydroxyethylcellulose, higher molecular weight Polyethylene glycol mono and diesters of fatty acids, polyacrylates, polyacrylamides and the like can still be supported.
- the microcapsules from the aqueous phase for example by decantation, filtration or centrifugation separated.
- Another object of the invention relates to the use of the microcapsules according to the invention for the preparation of cosmetic and / or pharmaceutical preparations, such as hair shampoos, hair lotions, bubble baths, shower baths, creams, gels, Lotions, alcoholic and aqueous / alcoholic solutions, emulsions, wax / fat masses, Stick preparations, powders or ointments.
- cosmetic and / or pharmaceutical preparations such as hair shampoos, hair lotions, bubble baths, shower baths, creams, gels, Lotions, alcoholic and aqueous / alcoholic solutions, emulsions, wax / fat masses, Stick preparations, powders or ointments.
- active ingredients, oil bodies and emulsifiers in unencapsulated form as already described above have been; a renewed enumeration is therefore omitted.
- they may also be food additives, for example additives for Sports nutrition and the like.
- the microcapsules can be used in amounts of these agents 1 to 50,
- Table 1 lists a number of formulation examples.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicinal Preparation (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polyesters Or Polycarbonates (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Description
Claims (10)
- Mikrokapseln mit mittleren Durchmessern im Bereich von 0,1 bis 5 mm, dadurch erhältlich, dass man(a) wäßrige Wirkstoffzubereitungen mit Ölkörpern in Gegenwart von Emulgatoren zu O/W-Emulsionen verarbeitet,(b) die so erhaltenen Emulsionen mit wäßrigen Lösungen anionischer Polymere behandelt,(c) die so erhaltene Matrix mit wäßrigen Chitosanlösungen in Kontakt bringt und(d) die so erhaltenen Verkapselungsprodukte von der wäßrigen Phase abtrennt.
- Verfahren zur Herstellung von Mikrokapseln mit mittleren Durchmessern im Bereich von 0,1 bis 5 mm, bei dem man(a) wäßrige Wirkstoffzubereitungen mit Ölkörpern in Gegenwart von Emulgatoren zu O/W-Emulsionen verarbeitet,(b) die so erhaltenen Emulsionen mit wäßrigen Lösungen anionischer Polymere behandelt,(c) die so erhaltene Matrix mit wäßrigen Chitosanlösungen in Kontakt bringt und(d) die so erhaltenen Verkapselungsprodukte von der wäßrigen Phase abtrennt.
- Verfahren nach Anspruch 2, dadurch gekennzeichnet, dass man Wirkstoffe einsetzt, die ausgewählt sind aus der Gruppe, die gebildet wird von Fetten und Wachsen, Perlglanzwachsen, Lecithinen, Phospholipiden, biogenen Wirkstoffen, UV-Lichtschutzfaktoren, Antioxidantien, Deodorantien, Antitranspirantien, Antischuppenmitteln, Filmbildnern, Insektenrepellentien, Selbstbräunem, Tyrosininhibitoren, Parfümölen und Farbstoffen.
- Verfahren nach den Ansprüchen 2 und/oder 3, dadurch gekennzeichnet, dass man Ölkörper einsetzt, die ausgewählt sind aus der Gruppe, die gebildet wird von Guerbetalkoholen auf Basis von Fettalkoholen mit 6 bis 18 Kohlenstoffatomen; Estern von linearen C6-C22-Fettsäuren mit linearen oder verzweigten C6-C22-Fettalkoholen; Estern von verzweigten C6-C13-Carbonsäuren mit linearen oder verzweigten C6-C22-Fettalkoholen; Estern von linearen C6-C22-Fettsäuren mit verzweigten Alkoholen; Estern von C18-C38-Alkylhydroxycarbonsäuren mit linearen oder verzweigten C6-C22-Fettalkoholen; Estern von linearen und/oder verzweigten Fettsäuren mit mehrwertigen Alkoholen und/oder Guerbetalkoholen; Triglyceriden auf Basis C6-C10-Fettsäuren; flüssigen Mono-/Di-/Triglyceridmischungen auf Basis von C6-C18-Fettsäuren; Estern von C6-C22-Fettalkoholen und/oder Guerbetalkoholen mit aromatischen Carbonsäuren; Estern von C2-C12-Dicarbonsäuren mit linearen oder verzweigten Alkoholen mit 1 bis 22 Kohlenstoffatomen oder Polyolen mit 2 bis 10 Kohlenstoffatomen und 2 bis 6 Hydroxylgruppen; pflanzlichen Ölen; verzweigten primären Alkoholen; substituierten Cyclohexanen; linearen und verzweigte C6-C22-Fettalkoholcarbonaten; Guerbetcarbonaten auf Basis von Fettalkoholen mit 6 bis 18 Kohlenstoffatomen; Estern der Benzoesäure mit linearen und/oder verzweigten C6-C22-Alkoholen; linearen oder verzweigten, symmetrischen oder unsymmetrischen Dialkylethern mit 6 bis 22 Kohlenstoffatomen pro Alkylgruppe; Ringöffnungsprodukten von epoxidierten Fettsäureestern mit Polyolen; Siliconölen sowie aliphatischen bzw. naphthenischen Kohlenwasserstoffen und Mineralölen.
- Verfahren nach mindestens einem der Ansprüche 2 bis 4, dadurch gekenntzeichnet, dass man nichtionische Emulgatoren einsetzt.
- Verfahren nach mindestens einem der Ansprüche 2 bis 5, dadurch gekennzeichnet, daß man nichtionische Emulgatoren einsetzt, die ausgewählt sind aus der Gruppe, die gebildet wird von Anlagerungsprodukten von 2 bis 30 Mol Ethylenoxid und/oder 0 bis 5 Mol Propylenoxid an lineare Fettalkohole mit 8 bis 22 Kohlenstoffatomen, an Fettsäuren mit 12 bis 22 Kohlenstoffatomen, an Alkylphenole mit 8 bis 15 Kohlenstoffatomen in der Alkylgruppe sowie Alkylamine mit 8 bis 22 Kohlenstoffatomen im Alkylrest; Alkyl- und/oder Alkenyloligoglykosiden mit 8 bis 22 Kohlenstoffatomen im Alk(en)ylrest und deren ethoxylierte Analoga; Anlagerungsprodukten von 1 bis 15 Mol Ethylenoxid an Ricinusöl und/oder gehärtetes Ricinusöl; Anlagerungsprodukten von 15 bis 60 Mol Ethylenoxid an Ricinusöl und/oder gehärtetes Ricinusöl; Partialestern von Glycerin und/oder Sorbitan mit ungesättigten, linearen oder gesättigten, verzweigten Fettsäuren mit 12 bis 22 Kohlenstoffatomen und/oder Hydroxycarbonsäuren mit 3 bis 18 Kohlenstoffatomen sowie deren Addukte mit 1 bis 30 Mol Ethylenoxid; Partialestern von Polyglycerin Polyethylenglycol, Trimethylolpropan, Pentaerythrit, Zuckeralkoholen Alkylglucosiden sowie Polyglucosiden mit gesättigten und/oder ungesättigten, linearen oder verzweigten Fettsäuren mit 12 bis 22 Kohlenstoffatomen und/oder Hydroxycarbonsäuren mit 3 bis 18 Kohlenstoffatomen sowie deren Addukte mit 1 bis 30 Mol Ethylenoxid; Mischestem aus Pentaerythrit, Fettsäuren, Citronensäure und Fettalkohol und/oder Mischester von Fettsäuren mit 6 bis 22 Kohlenstoffatomen, Methylglucose und Polyolen; Mono-, Di- und Trialkylphosphaten sowie Mono-, Di- und/oder Tri-PEGalkylphosphaten und deren Salzen; Wollwachsalkoholen; Polysiloxan-Polyalkyl-Polyether-Copolymeren; Block-Copolymeren; Polyalkylenglycolen sowie Glycerinrarbonat.
- Verfahren nach mindestens einem der Ansprüche 2 bis 6, dadurch gekennzeichnet, dass man anionische Polymere einsetzt, die ausgewählt sind aus der Gruppe, die gebildet wird von anionischen Polysacchariden, Poly(meth)acrylsäuren und deren Derivaten sowie Alginsäure und deren Salzen.
- Verfahren nach mindestens einem der Ansprüche 2 bis 7, dadurch gekennzeichnet, daß man Chitosane einsetzt, die ein durchschnittliches Molekulargewicht im Bereich von 10.000 bis 500.000 bzw. 800.000 bis 1.200.000 Dalton aufweisen.
- Verfahren nach mindestens einem der Ansprüche 2 bis 8, dadurch gekennzeichnet, dass man die Mikrokapseln bei pH-Werten im Bereich von 3 bis 4 herstellt.
- Verwendung von Mikrokapseln nach Anspruch 1 zur Herstellung von kosmetischen und/oder pharmazeutischen Mitteln oder Lebensmittelzubereitungen.
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE50011907T DE50011907D1 (de) | 2000-03-04 | 2000-03-04 | Mikrokapseln |
AT00104745T ATE313375T1 (de) | 2000-03-04 | 2000-03-04 | Mikrokapseln |
EP00104745A EP1129771B1 (de) | 2000-03-04 | 2000-03-04 | Mikrokapseln |
ES00104745T ES2253147T3 (es) | 2000-03-04 | 2000-03-04 | Microcapsulas. |
KR1020027011570A KR20030011784A (ko) | 2000-03-04 | 2001-02-03 | 스킨케어제 |
EP01907493A EP1261421B1 (de) | 2000-03-04 | 2001-02-03 | Hautbehandlungsmittel |
JP2001564884A JP2003525917A (ja) | 2000-03-04 | 2001-02-03 | スキンケア剤 |
US10/220,109 US20030044469A1 (en) | 2000-03-04 | 2001-02-03 | Skincare agents |
ES01907493T ES2253352T3 (es) | 2000-03-04 | 2001-02-03 | Productos para el cuidado de la piel. |
PCT/EP2001/001177 WO2001066240A1 (de) | 2000-03-04 | 2001-02-03 | Hautbehandlungsmittel |
DE50108380T DE50108380D1 (de) | 2000-03-04 | 2001-02-03 | Hautbehandlungsmittel |
AU2001235449A AU2001235449A1 (en) | 2000-03-04 | 2001-02-03 | Skincare agents |
PCT/EP2001/002069 WO2001066241A1 (de) | 2000-03-04 | 2001-02-23 | Mikrokapseln - vi |
US10/220,718 US20030064106A1 (en) | 2000-03-04 | 2001-02-23 | Microcapsules-vi |
JP2001564885A JP2003526640A (ja) | 2000-03-04 | 2001-02-23 | マイクロカプセル−vi |
AU2001252145A AU2001252145A1 (en) | 2000-03-04 | 2001-02-23 | Microcapsules - vi |
KR1020027011569A KR20030007446A (ko) | 2000-03-04 | 2001-02-23 | 마이크로캡슐 ―ⅵ |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00104745A EP1129771B1 (de) | 2000-03-04 | 2000-03-04 | Mikrokapseln |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1129771A1 EP1129771A1 (de) | 2001-09-05 |
EP1129771B1 true EP1129771B1 (de) | 2005-12-21 |
Family
ID=8168036
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00104745A Expired - Lifetime EP1129771B1 (de) | 2000-03-04 | 2000-03-04 | Mikrokapseln |
EP01907493A Expired - Lifetime EP1261421B1 (de) | 2000-03-04 | 2001-02-03 | Hautbehandlungsmittel |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01907493A Expired - Lifetime EP1261421B1 (de) | 2000-03-04 | 2001-02-03 | Hautbehandlungsmittel |
Country Status (9)
Country | Link |
---|---|
US (2) | US20030044469A1 (de) |
EP (2) | EP1129771B1 (de) |
JP (2) | JP2003525917A (de) |
KR (2) | KR20030011784A (de) |
AT (1) | ATE313375T1 (de) |
AU (2) | AU2001235449A1 (de) |
DE (2) | DE50011907D1 (de) |
ES (2) | ES2253147T3 (de) |
WO (2) | WO2001066240A1 (de) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6729878B2 (en) * | 1998-04-03 | 2004-05-04 | Morton Cohen | Composition and method for improving, altering, and treating teeth |
US20030206958A1 (en) * | 2000-12-22 | 2003-11-06 | Cattaneo Maurizio V. | Chitosan biopolymer for the topical delivery of active agents |
ATE301986T1 (de) * | 2000-09-01 | 2005-09-15 | Cognis Ip Man Gmbh | Kosmetische stiftzubereitung |
US20030216376A1 (en) * | 2002-03-20 | 2003-11-20 | Revital Lifshitz-Liron | Crystalline forms of quetiapine hemifumarate |
EP1359247B1 (de) * | 2002-04-30 | 2005-10-12 | Cognis IP Management GmbH | Mit Mikrokapseln ausgerüstete Fasern und textile Flächengebilde |
ES2437182T3 (es) * | 2002-05-02 | 2014-01-09 | Cognis Ip Management Gmbh | Microcápsulas (XVII) |
EP1378564A1 (de) * | 2002-07-05 | 2004-01-07 | Cognis Iberia, S.L. | Portionierte flüssige Wasch- und Reinigungsmittelzubereitungen |
DE10300186A1 (de) * | 2003-01-08 | 2004-07-22 | Cognis Deutschland Gmbh & Co. Kg | Kaugummizusammensetzung mit mikroverkapselten Wirkstoffen |
DE10300187B4 (de) * | 2003-01-08 | 2007-03-29 | Cognis Ip Management Gmbh | Kaugummizusammensetzung mit pflanzlichen Wirkstoffen |
ITMI20030385A1 (it) * | 2003-03-04 | 2004-09-05 | Intercos Italia S P A Ora Intercos S P A | Composizione cosmetica comprendente poliisoprene. |
EP1454610A1 (de) * | 2003-03-06 | 2004-09-08 | Cognis France S.A. | Kosmetische und/oder pharmazeutische Zubereitungen mikroverkapselte Pflanzenextrakte enthaltend |
DE10316001A1 (de) * | 2003-04-07 | 2004-10-21 | Goldschmidt Ag | Wässrige Formulierungen enthaltend Kombinationen aus anionischen und kationischen Tensiden zur Erzeugung einer Fließgrenze |
EP1660023B1 (de) * | 2003-08-27 | 2009-01-07 | Beiersdorf AG | Kapsel deren kapselhülle bei topischer anwendung nicht mehr gesondert wahrnehmbar ist |
DE10357639A1 (de) * | 2003-08-27 | 2005-03-24 | Beiersdorf Ag | Kosmetische und/oder dermatologische Kapsel |
JP2007503417A (ja) | 2003-08-27 | 2007-02-22 | バイヤースドルフ・アクチエンゲゼルシヤフト | 局部適用のための球状化粧品製剤 |
US7226607B2 (en) * | 2003-09-11 | 2007-06-05 | The Procter & Gamble Company | Compositions comprising a dispersant and microcapsules containing an active material and a stabilizer |
US7092796B2 (en) | 2003-11-14 | 2006-08-15 | Cardinal Health 303, Inc. | System and method for verifying connection of correct fluid supply to an infusion pump |
WO2005086976A2 (en) * | 2004-03-11 | 2005-09-22 | University Of Massachusetts | Biopolymer encapsulation and stabilization of lipid systems and methods for utilization thereof |
US20060141046A1 (en) * | 2004-05-06 | 2006-06-29 | Ivrea Pharmaceuticals, Inc. | Particles for the delivery of active agents |
WO2005107710A2 (en) * | 2004-05-06 | 2005-11-17 | Ivrea Pharmaceuticals, Inc. | Particles for the delivery of active agents |
US20060081361A1 (en) * | 2004-09-13 | 2006-04-20 | Gabbey Lawrence W | Oil cooler with integral filter |
US20080214669A1 (en) * | 2005-01-14 | 2008-09-04 | Lipo Chemicals Inc. | Composition and Method For Treating Hyperpigmented Skin |
EP1702674A1 (de) * | 2005-03-16 | 2006-09-20 | Cognis IP Management GmbH | Sichtbare Perle |
EP1869007A1 (de) * | 2005-04-14 | 2007-12-26 | Teva Pharmaceutical Industries Ltd | Verfahren zur herstellung von quetiapinfumaraten |
US20070148112A1 (en) * | 2005-12-28 | 2007-06-28 | Avon Products, Inc. | Foaming, color-changing topical composition and method of imparting a cosmetic effect |
US20070251139A1 (en) * | 2006-03-08 | 2007-11-01 | Creeger Samuel M | Pest control device and associated method |
US8993506B2 (en) | 2006-06-12 | 2015-03-31 | Rhodia Operations | Hydrophilized substrate and method for hydrophilizing a hydrophobic surface of a substrate |
EP1972361A1 (de) * | 2007-03-21 | 2008-09-24 | Cognis IP Management GmbH | Milde Reinigungszusammensetzung enthaltend eine verkapselte Farbstoffpartikel |
EP1972324A1 (de) * | 2007-03-21 | 2008-09-24 | Cognis IP Management GmbH | Verkapselte Liposomen |
WO2008157197A1 (en) | 2007-06-12 | 2008-12-24 | Rhodia Inc. | Mono-, di- and polyol alkoxylate phosphate esters in oral care formulations and methods for using same |
US7557072B2 (en) | 2007-06-12 | 2009-07-07 | Rhodia Inc. | Detergent composition with hydrophilizing soil-release agent and methods for using same |
US7524800B2 (en) | 2007-06-12 | 2009-04-28 | Rhodia Inc. | Mono-, di- and polyol phosphate esters in personal care formulations |
CA2690602C (en) | 2007-06-12 | 2017-02-28 | Rhodia Inc. | Hard surface cleaning composition with hydrophilizing agent and method for cleaning hard surfaces |
JP5210699B2 (ja) * | 2008-04-18 | 2013-06-12 | ピアス株式会社 | レチノイド安定化組成物並びにその組成物を配合した皮膚外用剤及び化粧料 |
US8426353B2 (en) * | 2008-06-16 | 2013-04-23 | Firmenich Sa | Process for preparing polyurea microcapsules |
TWI404544B (zh) | 2008-08-11 | 2013-08-11 | Colgate Palmolive Co | 含珠粒之口腔保健組成物 |
US20100062057A1 (en) * | 2008-09-10 | 2010-03-11 | Pronova BioPharma Norge AS. | Formulation |
IT1391451B1 (it) * | 2008-09-24 | 2011-12-23 | Canalini | Preparato per il trattamento della disfunzione erettile |
JP5844260B2 (ja) | 2009-09-24 | 2016-01-13 | ユニリーバー・ナームローゼ・ベンノートシヤープ | オイゲノール、テルピネオールおよびチモールを含む殺菌剤 |
ES2383271B1 (es) | 2010-03-24 | 2013-08-01 | Lipotec S.A. | Procedimiento de tratamiento de fibras y/o materiales textiles |
EA022986B1 (ru) | 2010-12-07 | 2016-04-29 | Юнилевер Нв | Композиция для ухода за полостью рта |
US8911780B2 (en) * | 2011-02-11 | 2014-12-16 | Zx Pharma, Llc | Multiparticulate L-menthol formulations and related methods |
EP2672981B1 (de) | 2011-02-11 | 2018-03-28 | Zx Pharma, Llc | Multipartikuläre l-menthol-formulierung und entsprechende verfahren |
GB201117231D0 (en) * | 2011-10-06 | 2011-11-16 | Givaudan Sa | Composition |
BR112014009479B8 (pt) | 2011-11-03 | 2019-01-29 | Unilever Nv | composição líquida de limpeza pessoal e método de desinfecção da superfície externa |
US9549891B2 (en) | 2012-03-19 | 2017-01-24 | The Procter & Gamble Company | Superabsorbent polymers and sunscreen actives for use in skin care compositions |
EP2867005B1 (de) * | 2012-06-29 | 2019-12-11 | Archer Daniels Midland Co. | Verfahren zum Herstellen eines Nanomaterials |
EP2988824B1 (de) | 2013-04-23 | 2018-11-07 | Zx Pharma, Llc | Magensaftresistente multipartikuläre zusammensetzung mit proteinöser subbeschichtung |
KR102043535B1 (ko) | 2015-06-29 | 2019-11-11 | 더 프록터 앤드 갬블 캄파니 | 피부 케어 조성물에서 사용하기 위한 초흡수성 중합체 및 전분 분말 |
US10512658B2 (en) * | 2015-09-16 | 2019-12-24 | Clutch, Inc. | Compositions for the treatment of sweating and methods for making same |
US10149805B2 (en) * | 2015-09-16 | 2018-12-11 | Clutch, Inc. | Compositions for the treatment of sweating and methods for making same |
CN105754046B (zh) * | 2016-03-17 | 2017-12-08 | 扬州大学 | 引发剂微胶囊的一种制备方法 |
CN105859952B (zh) * | 2016-04-27 | 2017-11-21 | 扬州大学 | 一种可控制释放毫米级胶囊的制备方法 |
WO2018169896A1 (en) * | 2017-03-16 | 2018-09-20 | The Procter & Gamble Company | Consumer product compositions comprising microcapsules |
GB201815293D0 (en) * | 2018-09-20 | 2018-11-07 | Givaudan Sa | Improvements in or relating to organic compounds |
EP3892257A4 (de) * | 2018-12-04 | 2022-12-14 | LG Household & Health Care Ltd. | Gehaltreiche retinoidkapsel mit verzögerter freisetzung und zusammensetzung zur verminderung von falten damit |
WO2022006032A1 (en) * | 2020-06-30 | 2022-01-06 | L'oreal | Cosmetic composition having retinol |
US20210401698A1 (en) * | 2020-06-30 | 2021-12-30 | L'oreal | Cosmetic composition having retinol |
NL2026204B1 (en) * | 2020-08-03 | 2022-04-08 | Iamfluidics Holding B V | Method of preserving a reactive active compound, capsule and formulation. |
US20220313586A1 (en) * | 2021-03-31 | 2022-10-06 | L'oreal | Cosmetic composition with glaucine, retinol and peptides to combat skin aging |
FR3131837A1 (fr) * | 2022-01-19 | 2023-07-21 | L'oreal | Composition stable comprenant un rétinoïde et un composé acide ascorbique |
WO2023120390A1 (en) * | 2021-12-20 | 2023-06-29 | L'oreal | Stable composition comprising retinoid and ascorbic acid compound |
CN114644956B (zh) * | 2022-04-29 | 2023-05-09 | 泰伦特生物工程股份有限公司 | 一种镝铁合金线切割液及其制备方法和使用方法 |
KR102470009B1 (ko) * | 2022-06-10 | 2022-11-23 | 주식회사 엘지생활건강 | 자외선 차단 효율 상승효과를 갖는 유기 자외선 차단제 캡슐 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6418440A (en) * | 1987-07-10 | 1989-01-23 | Dainippon Pharmaceutical Co | Micro-capsule |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991009119A1 (en) * | 1989-12-13 | 1991-06-27 | Trancel Corporation | Improved alginate microcapsules, methods of making and using same |
IL100096A (en) * | 1991-11-20 | 1996-03-31 | Univ Ramot | Method for entrapment of active materials in chitosan |
DE19712978A1 (de) * | 1997-03-27 | 1998-10-01 | Henkel Kgaa | Chitosanmikrosphären |
GB9814619D0 (en) * | 1998-07-06 | 1998-09-02 | Cole Polytechnique Fudurale De | Materials and methods relating to encapsulation |
-
2000
- 2000-03-04 ES ES00104745T patent/ES2253147T3/es not_active Expired - Lifetime
- 2000-03-04 EP EP00104745A patent/EP1129771B1/de not_active Expired - Lifetime
- 2000-03-04 AT AT00104745T patent/ATE313375T1/de not_active IP Right Cessation
- 2000-03-04 DE DE50011907T patent/DE50011907D1/de not_active Expired - Lifetime
-
2001
- 2001-02-03 DE DE50108380T patent/DE50108380D1/de not_active Expired - Lifetime
- 2001-02-03 JP JP2001564884A patent/JP2003525917A/ja active Pending
- 2001-02-03 EP EP01907493A patent/EP1261421B1/de not_active Expired - Lifetime
- 2001-02-03 US US10/220,109 patent/US20030044469A1/en not_active Abandoned
- 2001-02-03 WO PCT/EP2001/001177 patent/WO2001066240A1/de active IP Right Grant
- 2001-02-03 ES ES01907493T patent/ES2253352T3/es not_active Expired - Lifetime
- 2001-02-03 KR KR1020027011570A patent/KR20030011784A/ko not_active Application Discontinuation
- 2001-02-03 AU AU2001235449A patent/AU2001235449A1/en not_active Abandoned
- 2001-02-23 JP JP2001564885A patent/JP2003526640A/ja active Pending
- 2001-02-23 AU AU2001252145A patent/AU2001252145A1/en not_active Abandoned
- 2001-02-23 KR KR1020027011569A patent/KR20030007446A/ko not_active Application Discontinuation
- 2001-02-23 US US10/220,718 patent/US20030064106A1/en not_active Abandoned
- 2001-02-23 WO PCT/EP2001/002069 patent/WO2001066241A1/de active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6418440A (en) * | 1987-07-10 | 1989-01-23 | Dainippon Pharmaceutical Co | Micro-capsule |
Also Published As
Publication number | Publication date |
---|---|
AU2001235449A1 (en) | 2001-09-17 |
ES2253147T3 (es) | 2006-06-01 |
EP1129771A1 (de) | 2001-09-05 |
KR20030011784A (ko) | 2003-02-11 |
EP1261421A1 (de) | 2002-12-04 |
US20030064106A1 (en) | 2003-04-03 |
WO2001066240A1 (de) | 2001-09-13 |
ATE313375T1 (de) | 2006-01-15 |
ES2253352T3 (es) | 2006-06-01 |
KR20030007446A (ko) | 2003-01-23 |
JP2003525917A (ja) | 2003-09-02 |
EP1261421B1 (de) | 2005-12-14 |
WO2001066241A1 (de) | 2001-09-13 |
DE50011907D1 (de) | 2006-01-26 |
AU2001252145A1 (en) | 2001-09-17 |
DE50108380D1 (de) | 2006-01-19 |
JP2003526640A (ja) | 2003-09-09 |
US20030044469A1 (en) | 2003-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1129771B1 (de) | Mikrokapseln | |
EP1243323B1 (de) | Nanokapseln | |
EP1247568A1 (de) | Mikrokapseln (XIII) | |
EP1184027B1 (de) | Kosmetische Stiftzubereitung | |
DE10232774B4 (de) | Kosmetische Zubereitungen mit antibakteriellen Eigenschaften | |
DE10347940A1 (de) | Selbstemulgierende Zubereitungen | |
EP1243320B1 (de) | Mikrokapseln (VIII) | |
EP1243318B1 (de) | Mikrokapseln (VII) | |
EP1452167A1 (de) | Kosmetische, pharmazeutische und/oder dermatologische Zubereitungen enthaltend einen Extrakt aus Eperua falcata | |
EP1243321A1 (de) | Mikrokapseln(IX) | |
EP1479432B1 (de) | Mikrokapseln (XXIV) | |
EP1284127B1 (de) | Mikrokapseln (XV) | |
EP1462157B1 (de) | Mikrokapseln (XXIII) | |
EP1464385B1 (de) | Mikrokapseln (XVIII) | |
EP1430947A1 (de) | Mikropartikel mit flüssigkristallinen Kompartimenten | |
EP1428571A1 (de) | Mikrokapseln (XX) | |
EP1243324B1 (de) | Mikrokapseln (XII) | |
EP1243322A1 (de) | Mikrokapseln(X) | |
EP1243247A1 (de) | Emulsionen vom Typ W/O bzw. O/W/O enthaltend Mikrokapseln bestehend aus Wirkstoffen und thermogelierenden Heteropolysacchariden oder Proteinen | |
EP1264633A1 (de) | Verwendung von Alkyl(ether)phosphaten(I) | |
EP1398075B1 (de) | Polyamidmikrokapseln (IV) | |
EP1358930B1 (de) | Mikrokapseln (XVII) | |
EP1264632A1 (de) | Verwendung von Alkyl(ether)phosphaten(III) | |
EP1398076B1 (de) | Polyamidmikrokapseln (V) | |
EP1243319A1 (de) | Mikrokapseln (XI) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000304 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
AKX | Designation fees paid |
Free format text: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: COGNIS IBERIA, S.L. |
|
17Q | First examination report despatched |
Effective date: 20040511 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: COGNIS IP MANAGEMENT GMBH |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PETIT VILADOT, DR.,JOSEP-LLUIS Inventor name: GARCES GARCES, JOSEP |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20051221 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20051221 Ref country code: GB Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20051221 Ref country code: IE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20051221 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
REF | Corresponds to: |
Ref document number: 50011907 Country of ref document: DE Date of ref document: 20060126 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060304 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060321 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060321 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060321 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060331 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060331 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060331 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060331 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060522 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2253147 Country of ref document: ES Kind code of ref document: T3 |
|
GBV | Gb: ep patent (uk) treated as always having been void in accordance with gb section 77(7)/1977 [no translation filed] |
Effective date: 20051221 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FD4D |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
26N | No opposition filed |
Effective date: 20060922 |
|
BERE | Be: lapsed |
Owner name: COGNIS IP MANAGEMENT G.M.B.H. Effective date: 20060331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20051221 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20140325 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20140530 Year of fee payment: 15 Ref country code: FR Payment date: 20140328 Year of fee payment: 15 Ref country code: ES Payment date: 20140423 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 50011907 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150304 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20151130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151001 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150331 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20160427 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150305 |